Date: August 14, 2023

Administrative Circular: 2023:24

ATTN: Medical Health Officers and Branch Offices
      Public Health Nursing Administrators and Assistant Administrators
      Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products

Part 4 – Biological Products

Influenza Vaccines

2023/24 Seasonal Influenza Vaccines

- Influenza pages for the 2023/24 season have been revised.
- The eligibility criteria for publicly funded influenza vaccine are unchanged, however the group “Anyone else who wishes to reduce their risk of influenza” has been incorporated into “Recommended and provided free to people 6 months of age and older.”
- Revisions to the influenza pages include:
  - The vaccine strains contained in the 2023/24 influenza vaccines.
  - The following footnote has been added to the “Seasonal Influenza Vaccine Eligibility” page: “Indigenous peoples (including First Nations, Métis and Inuit) may be disproportionately affected by influenza because of longstanding inequities related to the social determinants of health due to the impacts of colonization.”
  - The “Intended Use of Influenza Vaccines” table has been revised to include the vaccines for the 2023/24 publicly funded program. The page has a link to the updated Question & Answer document for health care providers related to Influenza Vaccines for Adults 65 Years of Age and Older.
  - The expanded eligibility indications that had been added during the 2022/2023 influenza season for FLUZONE® HIGH-DOSE QUADRIVALENT and FLUAD® have been removed from the “Intended Use of Influenza Vaccines” and the respective product pages.
  - Product components for FLUAD® and FLULAVAL® TETRA have been updated to align with the product monographs.
Please remove the following pages:

- 2022/23 Seasonal Influenza Vaccine Eligibility: page 1 dated August 2022
- Safety Issues Applicable to Influenza Vaccines: page 1 dated August 2022
- Intended Use of Influenza Vaccines: page 1 dated December 2022
- FLUMIST® QUADRIVALENT: pages 1-3 dated November 2022
- AFLURIA® TETRA: pages 1-3 dated November 2022
- FLULAVAL® TETRA: page 1 & 2 dated November 2022
- FLUZONE® QUADRIVALENT: pages 1 & 2 dated November 2022
- FLUZONE® HIGH-DOSE QUADRIVALENT: pages 1 & 2 dated November 25, 2022
- FLUAD®: pages 1 & 2 dated December 2022

Please add the following pages:

- 2023/24 Seasonal Influenza Vaccine Eligibility: page 1 dated August 2023
- Safety Issues Applicable to Influenza Vaccines: page 1 dated August 2023
- Intended Use of Influenza Vaccines: page 1 dated August 2023
- FLUMIST® QUADRIVALENT: pages 1-3 dated August 2023
- FLULAVAL® TETRA: pages 1 & 2 dated August 2023
- FLUZONE® QUADRIVALENT: pages 1 & 2 dated August 2023
- FLUZONE® HIGH-DOSE QUADRIVALENT: pages 1 & 2 dated August 2023
- FLUAD®: pages 1 & 2 dated August 2023

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated August 2023 and replace with the enclosed updated Title Page and Table of Contents dated August 14, 2023.
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPF CACPIM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc:
Provincial Health Officer
Dr. Bonnie Henry

BC Ministry of Health,
Communicable Disease Prevention and Control,
Population & Public Health Division:

Bethany McMullen
Director, Immunizations

Brian Sagar
A/Executive Director